Compare RVPH & BLIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | BLIN |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.2M |
| IPO Year | N/A | 2018 |
| Metric | RVPH | BLIN |
|---|---|---|
| Price | $0.87 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $72.00 | $4.62 |
| AVG Volume (30 Days) | ★ 440.4K | 22.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,568,000.00 |
| Revenue This Year | N/A | $22.67 |
| Revenue Next Year | N/A | $21.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.69 |
| 52 Week High | $3.11 | $2.14 |
| Indicator | RVPH | BLIN |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 60.45 |
| Support Level | $0.44 | $0.92 |
| Resistance Level | $1.00 | $1.04 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 22.67 | 64.16 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.